{
    "clinical_study": {
        "@rank": "55248", 
        "acronym": "RENSYMPIS", 
        "arm_group": [
            {
                "arm_group_label": "Renal denervation", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients are randomized to renal denervation"
            }, 
            {
                "arm_group_label": "Optimization of medical therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Antihypertensive treatment is optimized"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypertension is a major risk factor for stroke and cardiovascular mortality. Catheter- based\n      renal denervation causes substantial and sustained blood- pressure reduction in patients\n      with resistant hypertension.\n\n      The purpose of RENSYMPIS is to study the effects of renal denervation on:\n\n        1. Cardiovascular function\n\n        2. Metabolic factors\n\n        3. Inflammatory and endocrine factors\n\n        4. Coagulation\n\n        5. Sleep"
        }, 
        "brief_title": "Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Resistant Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Insulin Resistance"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Resistant Hypertension (systolic blood pressure >160mmHg and 3 or more\n             antihypertensive agents in use)\n\n          -  Age 30- 69 years\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Secondary hypertension\n\n          -  Pseudohypertension\n\n          -  Pregnancy\n\n          -  Renal insufficiency (GFR <45ml/min)\n\n          -  Clinically significant stenotic valvular disease\n\n          -  Oral anticoagulation\n\n          -  CCS III-IV symptoms or CABG/PCI in previous 6 months\n\n          -  Prior stroke\n\n          -  Contrast agent allergy\n\n          -  inappropriate renal artery anatomy (< 4mm diameter, < 20mm length)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785732", 
            "org_study_id": "SA-007"
        }, 
        "intervention": {
            "arm_group_label": "Renal denervation", 
            "description": "Sympathetic renal denervation via renal arteries", 
            "intervention_name": "Renal Denervation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 8, 2013", 
        "location": {
            "contact": {
                "email": "tuomas.paana@satshp.fi", 
                "last_name": "Tuomas Paana, M.D", 
                "phone": "+358 2 6277100"
            }, 
            "facility": {
                "address": {
                    "city": "Pori", 
                    "country": "Finland"
                }, 
                "name": "Satakunta Central Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Tuomas Paana, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Antti Ylitalo, M.D. Ph.D", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Risto Kaaja, M.D. Ph.D.", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "tuomas.paana@satshp.fi", 
            "last_name": "Tuomas Paana, M.D.", 
            "phone": "+358 2 6277100"
        }, 
        "overall_contact_backup": {
            "email": "antti.ylitalo@satshp.fi", 
            "last_name": "Antti Ylitalo, M.D. Ph.D", 
            "phone": "+358 2 6277100"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: Institutional review board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Office blood pressure", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Ambulatory blood pressure", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Insulin resistance", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Endothelial function", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "The Hospital District of Satakunta", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The Hospital District of Satakunta", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}